BRPI0512394A - composições e métodos para co-distribuição de fármacos anticáncer, fármacos antiangiogênicos e um polissacarìdeo - Google Patents

composições e métodos para co-distribuição de fármacos anticáncer, fármacos antiangiogênicos e um polissacarìdeo

Info

Publication number
BRPI0512394A
BRPI0512394A BRPI0512394-1A BRPI0512394A BRPI0512394A BR PI0512394 A BRPI0512394 A BR PI0512394A BR PI0512394 A BRPI0512394 A BR PI0512394A BR PI0512394 A BRPI0512394 A BR PI0512394A
Authority
BR
Brazil
Prior art keywords
drugs
methods
compositions
distribution
polysaccharide
Prior art date
Application number
BRPI0512394-1A
Other languages
English (en)
Portuguese (pt)
Inventor
David Platt
Eliezer Zomer
Anatole Klyosov
Original Assignee
Pro Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro Pharmaceuticals Inc filed Critical Pro Pharmaceuticals Inc
Publication of BRPI0512394A publication Critical patent/BRPI0512394A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI0512394-1A 2004-06-22 2005-06-21 composições e métodos para co-distribuição de fármacos anticáncer, fármacos antiangiogênicos e um polissacarìdeo BRPI0512394A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58195804P 2004-06-22 2004-06-22
PCT/US2005/021827 WO2006002106A2 (en) 2004-06-22 2005-06-21 Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide

Publications (1)

Publication Number Publication Date
BRPI0512394A true BRPI0512394A (pt) 2008-03-11

Family

ID=35782284

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512394-1A BRPI0512394A (pt) 2004-06-22 2005-06-21 composições e métodos para co-distribuição de fármacos anticáncer, fármacos antiangiogênicos e um polissacarìdeo

Country Status (6)

Country Link
EP (1) EP1765365A4 (de)
JP (1) JP2008503583A (de)
CN (1) CN101267828A (de)
BR (1) BRPI0512394A (de)
CA (1) CA2570570A1 (de)
WO (1) WO2006002106A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723987C (en) 2008-05-14 2019-06-11 Agriculture Victoria Services Pty Ltd Use of angiogenin or angiogenin agonists for treating diseases and disorders
AU2013204721B2 (en) * 2008-05-14 2016-08-18 Agriculture Victoria Services Pty Ltd Methods for treating cachexia
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
AU2013204740C1 (en) * 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
FR3022462B1 (fr) * 2014-06-18 2018-04-27 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition orale d'anticorps anti-tnfalpha

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308838A (en) * 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US20020107222A1 (en) * 1993-03-01 2002-08-08 David Platt Modified polysaccharides for treatment of cancer
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
EP0958825A1 (de) * 1998-05-18 1999-11-24 Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) Synergistische Zusammensetzung zur Behandlung von Krebs, welche unverdauliche Kohlenhydrate und eines Antikrebsmittel enthält
DE50012701D1 (de) * 1999-09-06 2006-06-08 Guenther Beisel Vernetztes mittel zur erzeugung eines langanhaltenden sättigungseffekts und verfahren zu dessen herstellung
US7012068B2 (en) * 2001-03-27 2006-03-14 Pro-Pharmaceuticals, Inc. Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
KR20040045795A (ko) * 2002-11-25 2004-06-02 주식회사한국신약 펠리누스 린테우스에서 추출한 다당류와 마이토마이신ｃ를 포함하는 복합 항암제

Also Published As

Publication number Publication date
EP1765365A2 (de) 2007-03-28
JP2008503583A (ja) 2008-02-07
CA2570570A1 (en) 2006-01-05
CN101267828A (zh) 2008-09-17
WO2006002106A2 (en) 2006-01-05
EP1765365A4 (de) 2008-02-20
WO2006002106A3 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
Yempala et al. Expanding the arsenal of PtIV anticancer agents: Multi‐action PtIV anticancer agents with bioactive ligands possessing a hydroxy functional group
BR112022020769A2 (pt) Compostos de 2,4-dioxopirimidina de inibição de cd73
BR112021026142A2 (pt) Composto conjugado ligado à cadeia lateral da fórmula, célula de tumor, composição farmacêutica, agente quimioterapêutico, e, agentes sinergísticos
BRPI0407897A (pt) derivados de cianopiridina úteis no tratamento de cáncer e outros distúrbios
BR112014026730A2 (pt) conjugados fármaco-ligante de dr5
BR112023001359A2 (pt) Conjugado de anticorpo-fármaco anti-cd79b, método de preparação do mesmo e uso farmacêutico do mesmo
DE50107844D1 (de) Curcumin-derivate mit gegenüber curcumin verbesserter wasserlöslichkeit und diese enthaltende arzneimittel
NZ707534A (en) Pyrrolobenzodiazepine-antibody conjugates
NZ745069A (en) Pyrrolobenzodiazepines and conjugates thereof
BRPI0414017A8 (pt) pró-fármacos poliméricos de múltiplos braços
PT1951730E (pt) Derivados de pirimidina ligados a heteroalquilo
ATE342054T1 (de) Verfahren und zusammansetzung zur behandlung von krebs
BR0108930A (pt) Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente
BRPI0508814B8 (pt) derivados de carbolina, bem como uso dos mesmos e composição farmacêutica
NZ588913A (en) Liver cancer drug
AU2008222592B2 (en) Compositions and methods for delivery of anti-cancer agents
WO2009120697A3 (en) Method and compositions for treatment of cancer
PE20221459A1 (es) Conjugados anticuerpo-farmaco dirigido a claudina 18.2
JOP20240261A1 (ar) مترافقات جسم مضاد عقار لمركبات مضادة للورم وطرق استخدامها
BR112012017884A2 (pt) composto, composição farmacêutica, uso de um composto, derivado de pirazina, métodos para o tratamento ou prevenção, para promoção óssea, e, para tratar lesões ósseas em cânceres
FR2921927B1 (fr) Imidazo°1,2-a!quinoxalines et derives pour le traitement des cancers
MX2025011251A (es) Conjugados de ligando-fármaco citotóxico y usos farmacéuticos de estos
BR112023009912A2 (pt) Anticorpo anti-claudina 18.2 e conjugado anticorpo-fármaco do mesmo
BRPI0411092A (pt) benzo[b]tiofenos substituìdos com 3-arilsulfanila e com 3-heteroarilsulfanila como agentes terapêuticos
BRPI0512394A (pt) composições e métodos para co-distribuição de fármacos anticáncer, fármacos antiangiogênicos e um polissacarìdeo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.